Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vor Biopharma Inc.

2.20
+0.03001.38%
Post-market: 2.15-0.0500-2.27%19:14 EDT
Volume:3.11M
Turnover:6.60M
Market Cap:274.91M
PE:-1.54
High:2.21
Open:2.15
Low:2.03
Close:2.17
Loading ...

Vor Biopharma Announces Key Leadership Changes

TIPRANKS
·
23 Jul

Vor Bio appoints Cumbo, Detheux to board of directors

TIPRANKS
·
21 Jul

Press Release: Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Dow Jones
·
21 Jul

Vor Biopharma Inc. Files Initial Beneficial Ownership Statement for Director Michel Detheux

Reuters
·
19 Jul

Vor Biopharma Inc. Files Initial Statement of Beneficial Ownership for Director Alexander Cumbo

Reuters
·
19 Jul

BRIEF-Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
19 Jul

Vor Bio appoints Zuraw as Chief Development Officer

TIPRANKS
·
17 Jul

Vor Biopharma Appoints New CFO to Drive Growth

TIPRANKS
·
11 Jul

Vor Biopharma Names Sandy Mahatme as CFO, Chief Business Officer

MT Newswires Live
·
11 Jul

Vor Biopharma Inc. Files Initial Statement of Beneficial Ownership for CFO Sandesh Mahatme

Reuters
·
11 Jul

Form 144 | VOR BIOPHARMA INC. Officer Robert Ang proposes to sell 596,885 shares, with a total value of approximately $1.39 million.

Filings Track
·
11 Jul

Vor Bio appoints Sandy Mahatme as CFO, CBO

TIPRANKS
·
11 Jul

Press Release: Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Dow Jones
·
11 Jul

BRIEF-Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Reuters
·
02 Jul

Unusually active option classes on open July 1st

TIPRANKS
·
01 Jul

Sector Update: Health Care Stocks Higher Late Afternoon

MT Newswires Live
·
01 Jul

Vor Biopharma Shares Surge After Upgrade From HC Wainwright

MT Newswires Live
·
01 Jul

Top Midday Gainers

MT Newswires Live
·
01 Jul

Vor Biopharma Raised to Buy From Neutral by HC Wainwright & Co.

Dow Jones
·
30 Jun

Vor Biopharma’s Strategic Licensing and Growth Potential Justifies Buy Rating

TIPRANKS
·
30 Jun